Gastrax en es it fr

Gastrax Brand names, Gastrax Analogs

Gastrax Brand Names Mixture

  • No information avaliable

Gastrax Chemical_Formula


Gastrax RX_link

Gastrax fda sheet

Gastrax FDA

Gastrax msds (material safety sheet)

Gastrax Synthesis Reference

R. P. Pioch, U.S. Pat. 4,375,547 (1982)

Gastrax Molecular Weight

331.46 g/mol

Gastrax Melting Point

203 oC

Gastrax H2O Solubility


Gastrax State


Gastrax LogP


Gastrax Dosage Forms

Capsule (150, 300 mg)

Gastrax Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.

Gastrax Pharmacology

Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.

Gastrax Absorption

Rapid (bioavailability of nizatidine exceeds 70%)

Gastrax side effects and Toxicity

Oral, rat LD50: 301 mg/kg. Symptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea.

Gastrax Patient Information

Gastrax Organisms Affected

Humans and other mammals